U.S. Markets
Pfizer's (PFE) Elrexfio demonstrated a clinically meaningful and statistically significant benefit for patients whose disease progressed after anti-CD38 therapy and lenalidomide in the Phase 3 MagnetisMM-32 trial
ORIGINAL · NewsquawkPfizer's (PFE) Elrexfio demonstrated a clinically meaningful and statistically significant benefit for patients whose disease progressed after anti-CD38 therapy and lenalidomide in the Phase 3 MagnetisMM-32 trial
StockNow breaking-news AI analysis
The headline reports a significant, clinically meaningful Elrexfio benefit in a specified MagnetisMM-32 patient group, but provides no numerical results or trial details.
Related stocks
1 stocks
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.